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Abstract
Objective: Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse
effects. The study’s primary objective was to determine whether abacavir/lamivudine + atazanavir (ABC/3TC+ATV) was
virologically non-inferior to tenofovir/emtricitabine + atazanavir/ritonavir (TDF/FTC+ATV/r) over 24 weeks in a population of
virologically suppressed, HIV-1 infected patients.
Design: This open-label, multicenter, non-inferiority study enrolled antiretroviral experienced, HIV-infected adults currently
receiving a regimen of TDF/FTC+ATV/r for $6 months with no history of virologic failure and whose HIV-1 RNA had been #
75 copies/mL on 2 consecutive measurements including screening. Patients were randomized 1:2 to continue current
treatment or simplify to ABC/3TC+ATV.
Methods: The primary endpoint was the proportion of patients with HIV-RNA,50 copies/mL at Week 24 by the Time to
Loss of Virologic Response (TLOVR) algorithm. Secondary endpoints included alternative measures of efficacy, adverse
events (AEs), and fasting lipids. Exploratory endpoints included inflammatory, coagulation, bone, and renal biomarkers.
Results: After 24 weeks, ABC/3TC+ATV (n = 199) was non-inferior to TDF/FTC+ATV/r (n = 97) by both the primary analysis
(87% in both groups) and all secondary efficacy analyses. Rates of grade 2–4 AEs were similar between the two groups (40%
vs 37%, respectively), but an excess of hyperbilirubinemia made the rate of grade 3–4 laboratory abnormalities higher in the
TDF/FTC+ATV/r group (30%) compared with the ABC/3TC+ATV group (13%). Lipid levels were stable except for HDL
cholesterol, which increased significantly in the ABC/3TC+ATV group. Bone and renal biomarkers improved significantly
between baseline and Week 24 in patients taking ABC/3TC+ATV, and the difference between groups was significant at
Week 24. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment
groups.
Conclusions: After 24 weeks, simplification to ABC/3TC+ATV from TDF/FTC+ATV/r maintained viral suppression was well-
tolerated, and led to improvements in bone and renal biomarkers and HDL cholesterol.
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Introduction
Atazanavir (ATV) is a well-tolerated protease inhibitor (PI)
whose plasma concentration and genetic barrier to resistance are
improved by coadministration with low-dose ritonavir (RTV)
[1,2]. However, use of RTV is associated with higher rates of
gastrointestinal adverse events, elevated lipid levels and, when
given with ATV, an increased risk of indirect hyperbilirubinemia
[1,3–5]. As an inhibitor of the CYP3A metabolic pathway, RTV
also interacts with many drugs and co-administration is contra-
indicated for a number of antiarrhythmics, ergot derivatives,
sedative/hypnotics, and statins, among others. [4].
Numerous induction-maintenance strategies in which RTV is
discontinued once viral suppression has been achieved have
been investigated and have been found to be effective [5–13].
Treatment guidelines from the US Department of Health and
Human Services (DHHS) endorse these types of regimen
simplifications, citing the benefits of reduced pill burden, enhanced
tolerability, improved quality of life, and decreased risk of some
long-term toxicities [14].
The primary objective of the study was to determine whether
abacavir/lamivudine + atazanavir (ABC/3TC+ATV) was viro-
logically non-inferior to tenofovir/emtricitabine + atazanavir/
ritonavir (TDF/FTC+ATV/r) over 24 weeks in a population of
virologically suppressed HIV-1 infected patients with no history of
prior virologic failure whose virus was currently suppressed on a
regimen of TDF/FTC plus ATV/r) one of four preferred first-line
regimens in the DHHS guidelines [14]. An induction-maintenance
strategy is particularly well-suited to ATV, which is licensed in the
United States for use either unboosted (daily dose of ATV 400 mg)
or boosted (daily dose of ATV 300 mg and RTV 100 mg) [5].
However, since TDF/FTC is not recommended for use with
unboosted ATV because of a drug-drug interaction that results in
decreased concentrations of ATV [5], patients in this trial who
were randomized to discontinue RTV simultaneously switched to
a nucleoside reverse transcriptase inhibitor (NRTI) backbone of
abacavir sulfate/lamivudine (ABC/3TC).
This paper presents the primary endpoint of the study
(percentage of patients maintaining viral suppression at Week
24) and associated secondary analyses including immunologic
response, virologic efficacy, HIV-1 genotypic and phenotypic
resistance patterns in patients who experienced confirmed
virologic failure as well as the tolerability and safety of these
regimens, including changes from baseline in fasting lipids and
biomarkers associated with cardiovascular, bone, and renal health.
Methods
The ASSURE study (EPZ113734; NCT01102972) was a
prospective, randomized, multicenter, open-label, phase IV study
in HIV-infected, HLA-B*5701-negative patients $18 years of age
who were virologically suppressed (defined as HIV-1 RNA #75
copies/mL on 2 consecutive occasions; screening and $28 days
prior) on a once-daily regimen of TDF/FTC (300 mg/200 mg)
and ATV/r (300 mg/100 mg) for $6 months immediately prior
to screening.
The study design, outcome measures and results summary are
also available on the ClinicalTrials.gov site (http://clinicaltrials.
gov; registration number is NCT01102972) as well as on the
GlaxoSmithKline Clinical Trials registry (http://www.gsk-
clinicalstudyregister.com; GSK ID number 113734). The CON-
SORT Checklist has been included as supplementary material
(Checklist S1).
The full study protocol has been included as supplementary
material (Protocol S1), and contains the full listing of all inclusion
and exclusion criteria. The main inclusion criteria included a
requirement that enrolled patients were ART-experienced, HIV-1
infected and $18 years of age and receiving a once-daily regimen
of TDF/FTC (300 mg/200 mg)+ATV/r (300 mg/100 mg) for at
least 6 months prior to the first day of Screening. TDF/FTC+
ATV/r must have been the subject’s initial regimen or first or
second switch regimen. Initial regimen was defined as the first
regimen received by a previously antiretroviral-naı̈ve patient and
any change of ART whether of a single drug or multiple drugs
simultaneously was considered a regimen switch. Patients must not
have switched due to virologic failure. If TDF/FTC+ ATV/r was
the patient’s first or second switch regimen, then the subject should
have received any of the following prior regimens: any currently
licensed non-nucleotide reverse transcriptase inhibitor (NNRTI) in
combination with either TDF/FTC or zidovudine (ZDV)/3TC; a
ritonavir-boosted PI in combination with TDF/FTC or ZDV/
3TC. Alternative prior regimens not listed above were allowed on
a case-by-case basis. Each patient must have been virologically
suppressed (defined as HIV-1 RNA#75 copies/mL) at two
consecutive time points on TDF/FTC+ATV/r which had to
include the Screening visit and one additional visit at least 28 days
prior to Screening. The original protocol was amended on 07
September 2010 to define virologic suppression as HIV-1 RNA#
75 copies/mL; for patients enrolled prior to that date, the original
protocol required suppression of HIV-1 RNA to #50 copies/m.
The main patient exclusion criteria included having active CDC
Clinical Category C disease, ongoing clinically relevant hepatitis
and/or chronic hepatitis B infection (HBsAg+), being HLA-
B*5701 positive, prior abacavir exposure, creatinine clearance ,
50 ml/min via the Cockroft-Gault method, and known hypersen-
sitivity to any component of the study drugs. Patients were also
deemed ineligible if enrolled in one or more investigational drug
protocols within 30 days of screening, if they had been immunized
within 30 days prior to first dose of any study drugs or had been
treated with or had an anticipated need during the study for any
medications which could interact with the study medications
according to the product labeling. Exclusion criteria also included
treatment with immune-modulating agents within the prior 90
days, immunization with an HIV-1 immunotherapeutic vaccine,
or undergoing treatment with radiation therapy or cytotoxic
chemotherapeutic agents (or having an expected need for the latter
during the study). Any verified Grade 4 laboratory abnormality at
screening was generally exclusionary unless the investigator
provided a compelling explanation, as was any other laboratory
abnormality or medical condition detected at screening that the
investigator determined would have precluded the patient’s
participation in the study. While a baseline genotype was not
required for study entry, patients were deemed ineligible if they
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had known HIV genotyping results that indicated the presence of
any mutation in the reverse transcriptase or protease regions that
was associated with resistance to any study drug and included the
following reverse transcriptase mutations: K65R, K70E, L74V,
M184I/V, or Y115F, a combination of two or more thymidine
analog mutations: M41L, D67N, K70R, K219Q or E that must
include a change at either L210 or T215, or three or more of the
following HIV-1 protease mutations associated with atazanavir
resistance: D30, V32, M36, M46, I47, G48, I50, I54, A71, G73,
V77, V82, I84, N88, and L90. There were no restrictions on
screening CD4+ cell count. Females of child-bearing potential
were eligible if they had negative pregnancy tests at screening and
baseline and agreed to use $1 protocol-prescribed method of
contraception throughout the study.
Ethics Statement
The protocol (Protocol S1) was approved by the institutional
review board (IRB) used by the 44 participating study sites. These
IRBs included: Chesapeake Research Review, Inc., University (U)
of Tennessee IRB, Alameda County Medical Centre IRB;
Michigan State U Biomedical and Health IRB; Minneapolis
Human Subjects Research Committee; Georgetown U IRB;
Western IRB; St. Michaels Medical Center IRB, New York
Medical College IRB, Kaiser Permanente Center for Health
Research IRB and the Office of Human Research Ethics U of
North Carolina IRB. All patients provided written informed
consent to participate in the study.
Design and Intervention
After stratification by prior ART experience (TDF/FTC+
ATV/r as initial regimen or as first/second switch regimen),
eligible patients were randomized 2:1 to simplify to their regimen
to once-daily fixed dose combination of ABC/3TC 600 mg/
300 mg; (ViiV Healthcare, Research Triangle Park, NC) plus
ATV 600 mg (Bristol-Myers Squibb, Princeton, NJ) or remain on
the fixed dose combination of TDF/3TC (Gilead Sciences, Foster
City, CA) plus ATV boosted with RTV (AbbVie, Chicago, IL).
Randomization (by parallel group, stratified, and centralized with
a fixed block size of 3) and study drug provisioning were
performed by GlaxoSmithKline’s Randomization and Medication
Ordering System (RAMOS), which uses interactive voice-response
technology.
Procedures and Assessments
Patients were evaluated at screening, baseline, and weeks 2, 4,
12, and 24 with routine chemistry, hematology, and immunology
tests conducted at each assessment. The concentrations of specific
biomarkers (bone alkaline phosphatase, parathyroid hormone, C-
terminal telopeptide, osteocalcin, urine b2 microglobulin/creati-
nine ratio, high-sensitivity C reactive protein [hs-CRP], interleu-
kin-6, and D-dimer) were evaluated at baseline and Week 24 only.
Biomarker data was log-transformed prior to analysis and the
change from baseline was assessed using geometric mean ratios
with 95% confidence intervals. HIV-RNA concentrations were
measured by the Abbott RealTime HIV-1 Assay. Adverse events
(AEs) and laboratory toxicities were graded using the 2004
Division of AIDS Toxicity Grading Scale. All suspected ABC
hypersensitivity events were reported as serious adverse events
(SAEs). Glomerular filtration rates (GFR) were estimated using the
modification of diet in renal disease (MDRD) formula [15].
Smoking status and presence of diabetes were assessed at baseline
and Week 24 for Framingham Risk Score calculation [16] and
treatment emergent changes in fasting total cholesterol, HDL,
LDL, and triglycerides were assessed using the Division of AIDS
lipid toxicity grading system [17].
Viral genotypes and phenotypes were performed at Monogram
Biosciences Inc. (South San Francisco, California, USA). Geno-
typic mutations were defined according to International AIDS
Society-USA Guidelines [2].
All other laboratory tests were performed centrally by Quest
Diagnostics (Van Nuys, California, USA). Laboratory staff at
Monogram and Quest performing assessments were blinded as to
patient treatment assignment and sample labels included no
information on assigned treatment regimen.
Study Populations
The Intent-To-Treat (ITT) population consisted of all enrolled
subjects randomized in the study, regardless of what treatment was
actually received or the eventual outcome of study participation. A
modified ITT population, ITT-Exposed, including all subjects
who are in the ITT population and received at least one dose of
study drug, was the primary population for efficacy analyses. The
safety population consisted of all randomized subjects with the
exception of those with documented evidence of not having
consumed any investigational product. The virologic failure
population for the virology analysis included all subjects who
met the protocol virologic failure criterion which was defined as
plasma HIV-RNA $400 copies/mL on 2 consecutive occasions
(confirmed virologic failure). The Observed dataset contains all
data collected while subjects were in the study. No missing values
were imputed.
Outcome Measures
The primary efficacy endpoint of this study was the proportion
of patients with plasma HIV-1 RNA,50 copies/mL at Week 24
by the Time to Loss of Virologic Response (TLOVR) algorithm
stratified by prior ART experience (TDF/FTC+ATV/r as initial
regimen or as first/second switch regimen). The analysis was based
on the intent-to-treat (ITT) exposed population, which included all
patients exposed to at least 1 dose of any study drug. A study
responder at week 24 was defined as a patient who had achieved
confirmed (2 consecutive) plasma HIV-1 RNA,50 copies/mL
and remained suppressed (no confirmed viral rebound measure-
ments) by week 24 as defined by TLOVR algorithm. All others,
including those who did not complete week 24 assessments, were
defined as study non-responders.
Secondary endpoints measured at Week 24 included the
percentage of patients with HIV-RNA,50 copies/mL as mea-
sured by the missing/discontinuation equals failure (MD = F)
analysis and in the Observed dataset, the percentage of patients
with HIV-RNA,400 copies/mL as measured by TLOVR,
MD = F and Observed analyses, the change from baseline in
CD4+ cell count, time to virologic failure, detection of genotypic
and phenotypic resistance at the time of virologic failure, change
from baseline in fasting lipid profiles (total cholesterol, LDL, HDL,
triglycerides), grade 2–4 AEs, and all SAEs. There were two
exploratory endpoints: (1) change from baseline in neurocognition
scores, which will be discussed in a separate manuscript; and (2)
change from baseline in eight cardiovascular/inflammation, bone,
and renal biomarkers.
Statistical Analyses
A total of 300 patients were planned for the study. Three
hundred patients with a 2:1 ratio would provide over 90% power
to assess the non-inferiority of ABC/3TC+ATV over TDF/FTC-
ATV/r at the 0.05 level of significance. This sample size
calculation assumed a virologic response rate (proportions of
Simplification Improves Bone and Renal Biomarkers
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e96187
patients with HIV-1 RNA,50 copies/mL) of 89% in both
treatment groups and a non-inferiority margin of 12%. Non-
inferiority was defined as a 2-sided 95% confidence interval (CI)
that excluded differences as large as 12% in the direction of
inferiority of ABC/3TC+ATV group. The non-inferiority margin
of 12% is standard in such non-inferiority trials of ART and is
accepted by the FDA. To establish non-inferiority, the 2-sided
95% CI should lie entirely to the right of the value of 212%.
All the statistical comparisons were based on 2-sided signifi-
cance level of 0.05. Virologic response rates were compared using
a Cochran-Mantel-Haenszel test stratified by initial ART regimen.
Continuous variables were assessed by Wilcoxon rank-sum test,
whereas binary responses were compared by Fisher’s exact test.
The statistical analyses were performed using SAS Version 9.1
(SAS Institute Inc., Cary, NC) on a UNIX platform.
Results
Patient Characteristics and Accountability
This study enrolled 297 patients from clinical sites the United
States and Puerto Rico; 1 patient randomized to the TDF/FTC+
ATV/r was withdrawn due to a protocol violation prior to
receiving any study medication such that the exposed population
included 199 simplifying to ABC/3TC+ATV and 97 continuing
TDF/FTC+ATV/r (Figure 1). Patients were recruited between
April 2010 through December 2011, and the last 24-week analysis
visit occurred in June, 2012. Most (79%) were male (Table 1), with
34% of patients being of African-American/African heritage and
26% declaring themselves to be Hispanic/Latino. The median
baseline CD4+ cell count was 491.5 cells/mL. Median time on
ART prior to enrollment was 978 days for the ABC/3TC+ATV
group and 1106 days for the TDF/FTC+ATV/r group.
Ninety-one percent (268/296) of randomized patients in the
overall ITT-E population completed 24 weeks on study (Figure 1).
Two patients in the ABC/3TC+ATV treatment group and 3
patients in the TDF/FTC+ATV/r treatment group who com-
pleted 24 weeks on study were allowed to switch to an alternate
regimen during this period for appropriate patient management as
specified in the protocol (Protocol S1). The most common
reasons for study withdrawal were consent withdrawn (3% [9/
296]), adverse events (3% [9/296]), and lost to follow-up (2% [7/
296]).
Non-inferiority Analysis
The primary study endpoint was the proportion of patients with
HIV-1 RNA,50 copies/mL at Week 24 by the TLOVR analysis.
Following randomization, 86.9% (173/199) of patients in the
ABC/3TC+ATV treatment group successfully maintained HIV-
1 RNA below 50 copies/mL at Week 24 compared to 86.6% (84/
97) of patients taking TDF/FTC+ATV/r. The adjusted treatment
difference was 0.33%, and the two sided 95% CI (27.97% to
8.64%) stratified by prior ART excluded the predefined non-
inferiority margin of 212%, demonstrating the non-inferiority of
Figure 1. Patient disposition. Primary reasons for withdrawal were listed by the investigator on the case report form. *All adverse events leading
to study discontinuation were grade 1 or 2, with the exception of a grade 3 lipase increase in one patient continuing on TDF/FTC+ATV/r.
doi:10.1371/journal.pone.0096187.g001
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the ABC/3TC+ATV simplification regimen to the TDF/FTC+
ATV/r continuation regimen.
Secondary Virologic and Immunologic Response
Analyses
Secondary analyses of HIV-1 RNA,50 copies/mL were
similarly robust, with an Observed analysis response rate of 95%
(171/181) vs. 98% (87/89) and an MD = F analysis response rate
of 85% (169/199) vs. 88% (85/97), respectively, for the ABC/
3TC+ATV and TDF/FTC+ATV/r groups. The TLOVR
analysis of HIV-1 RNA,400 copies/mL also supported non-
inferiority, with response rates of 88.4% (176/199) in the ABC/
3TC+ATV group vs. 86.6% (84/97) for the TDF/FTC+ATV/r
group, with an adjusted TLOVR treatment difference of 1.84%
(95% CI: 26.33,10.02).
The mean increase in CD4+ cell count from baseline to Week
24 was significantly larger (P = 0.013) for the ABC/3TC+ATV
group (+48 cells/mL) compared with the TDF/FTC+ATV/r
group (+8 cells/mL). At Week 24, mean CD4+ cell counts were
569 and 562 cells/mL for ABC/3TC+ATV and TDF/FTC+
ATV/r, respectively.
Virology Results
HIV-1 genotypic and phenotypic analysis was performed if a
patient met confirmed virologic failure by having an HIV-RNA $
400 copies/mL on 2 consecutive occasions. Confirmed virologic
failure occurred in 2 patients switched to ABC/3TC+ATV and 1
patient continuing on TDF/FTC+ATV/r. Virus from 2 of the
patients (1 on ABC/3TC+ATV and 1 on TDF/3TC+ATV/r) had
full phenotypic susceptibility to all drugs tested, with no reverse
transcriptase mutations and a few minor protease mutations
(D60E from the patient on ATC/3TC+ATV/r; I62V, L10I, and
V77I from the patient on TDF/FTC+ATV/r). The second
patient taking ABC/3TC+ATV experienced initial rebound at
Week 2 with virologic failure confirmed at Week 4, concomitant
with site reports of the patient experiencing adherence issues.
Virus from this patient had reduced phenotypic susceptibility to
multiple drugs, including ABC, 3TC and ATV, and numerous
reverse transcriptase (M41L, L74V, K103N, M184V, L210W, and
T215Y) and protease (L10F, K20I, M46I, I54V, I62V, L63P,
A71T, G73T, I84V, and L90M) mutations. The patient reported
previous treatment with nevirapine plus TDF/FTC for .8 years
before switching to TDF/FTC+ATV/r, but prior viral resistance
was unknown because the patient had no HIV-1 genotypes
available for review at screening.
Safety and Tolerability Results
Rates of AEs of moderate or greater severity (grade 2–4) were
similar between the two groups (40% [79/199] for ABC/3TC+
ATV and 37% [36/97] for TDF/FTC+ATV/r; Table 2), with
only upper respiratory tract infection observed in $5% of patients
in either treatment group (4% [5/199] for ABC/3TC+ATV and
6% [6/97] for TDF/FTC+ATV/r). There were few grade 2–4
treatment-related AEs in either group (8% [16/199] for ABC/
3TC+ATV and 5% [6/97] for TDF/FTC+ATV/r). Five patients
experienced grade 2–4 cardiac disorders, but none were consid-
ered to be drug related. In the TDF/FTC+ATV/r group, one
patient had grade 2 palpitations. In the ABC/3TC+ATV group,
two patients had grade 2 cardiomyopathy, one patient had grade 2
coronary artery disease, and one patient (a former smoker with
diabetes, hyperlipidemia and a family history of cardiovascular
disease) had a grade 4 acute inferior myocardial infarction.
AEs leading to study withdrawal affected 4% (7/197) of patients
simplified to ABC/3TC+ATV and 2% (2/97) of patients
continuing on TDF/FTC+ATV/r, with only rash and nausea
reported in .1 patient. Suspected ABC hypersensitivity was
Table 1. Baseline patient demographics and characteristics.
ABC/3TC+ATV (N = 199) TDF/FTC+ATV/r (N = 97)
Median age, years (range) 44 (21–66) 42 (20–68)
Male, n (%) 155 (78) 79 (81)
Race, n (%)
African American/African Heritage 65 (33) 37 (38)
White/Caucasian/European Heritage 122 (61) 55 (57)
Other 12 (6) 5 (5)
Hispanic or Latino Ethnicity, n (%) 51 (26) 26 (27)
Median plasma HIV-1 RNA, log10 copies/mL 1.59 1.59
,50 copies/mL, n (%) 192 (96) 93 (96)
50 to 74 copies/mL, n (%) 2 (1) 2 (2)
$75 copies/mL, n (%) 5 (3) 2 (2)
Median CD4+ cell count, cells/mL (range) 492 (77–1196) 480 (108–1479)
,200 cells/mL, n (%) 14 (7) 6 (6)
CDC classification for HIV infection, n (%)
Category A 136 (68) 67 (69)
Category B 26 (13) 13 (13)
Category C 37 (19) 17 (18)
Hepatitis C coinfection, n (%) 18 (9) 8 (8)
Median time on prior ART, days (range) 978 (177–4830) 1106 (199–7078)
ART = antiretroviral therapy.
doi:10.1371/journal.pone.0096187.t001
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reported for 1 subject who was not withdrawn from the study but
restarted his original TDF/FTC +ATV/r regimen with resolution
of signs and symptoms.
The rate of treatment-emergent or worsening grade 2–4 and
grade 3–4 laboratory abnormalities was significantly higher (P,
0.001) in the TDF/3TC+ATV/r group compared with the ABC/
3TC+ATV group. The difference was primarily driven by changes
in total bilirubin; other treatment-emergent grade 3–4 lab
abnormalities were infrequent and similar between groups. Fasting
lipid levels (Figure 2) were similar between treatment groups and
varied little between baseline and Week 24, except for fasting
HDL, which increased significantly from baseline for the ABC/
3TC+ATV group (median change +3 mg/dl; P,0.001) compared
to the TDF/3TC+ATV/r group.
At baseline, the median estimated glomerular filtration rate
(calculated using the MDRD equation) was 93 mL/min/1.73 m2
for both treatment groups. At Week 24, the rate was similar
between the two groups, with a small median increase of 1 mL/
min/1.73 m2 for the ABC/3TC+ATV group and no change from
baseline in the TDF/FTC+ATV/r group. At baseline, the median
10-year risk of coronary heart disease (calculated using the
Framingham equation) was 2.0% in the ABC/3TC+ATV group
and 1.5% in the TDF/FTC+ATV/r group. Over 24 weeks on
randomized treatment, there was no change in 10-year risk in
either group.
Table 2. Adverse events (AEs) and laboratory abnormalities.
ABC/3TC+ATV (N = 199) TDF/FTC+ATV/r (N = 97)
n (%) n (%)
Grade 2–4 AEs
Any 79 (40) 36 (37)
Occurring in $5% of patients in either treatment group
Upper respiratory tract infection 7 (4) 6 (6)
Treatment related* 16 (8) 6 (6)
Nausea 4 (2) 2 (2)
Abnormal dreams 2 (1) 0
Dizziness 2 (1) 0
Severe or grade 3–4 AEs
Any{ 21 (11) 10 (10)
Treatment related 0 2 (2)
Blood bilirubin increased 0 1 (1)
Lipase increased 0 1 (1)
Serious AEs
Any` 16 (8) 5 (5)
Treatment related 1 (1) 0
Drug hypersensitivity 1 (1) 0
AEs leading to study withdrawal 7 (4) 2 (2)
Rash 2 (1) 0
Nausea 2 (1) 0
Treatment-emergent laboratory abnormalities
Any grade 2–4 event1 75 (38) 58 (60)
Any grade 3–4 event1 35 (13) 29 (30)
Treatment-emergent grade 3–4 events1
Total bilirubin1 8 (4) 24 (25)
Lipase 5 (3) 2 (2)
Inorganic phosphorus 5 (3) 0
Creatine kinase 4 (2) 3 (3)
Glucose 4 (2) 1 (1)
LDL cholesterol calculation 0 2 (2)
Aspartate amino transferase 1 (,1) 0
Total neutrophils 1 (,1) 0
*Listing includes all events occurring in .1 patient.
{No single event occurred in .3 patients.
`No single event occurred in .2 patients.
1P,0.001 using Fisher’s exact test.
doi:10.1371/journal.pone.0096187.t002
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Biomarkers
Between baseline and Week 24, the within-group decrease
(improvement) in all 4 measured bone biomarkers (bone alkaline
phosphatase, parathyroid hormone, C-terminal telopeptide and
osteocalcin) was significant (P,0.001) for patients taking ABC/
3TC+ATV (Figure 3A–D). These same biomarkers were relatively
unchanged in patients taking TDF/FTC+ATV/r over the same
time period. Comparing the two treatment groups, the decrease
from baseline to Week 24 in all 4 bone biomarkers was
significantly larger (P,0.001) for ABC/3TC+ATV than for
TDF/FTC+ATV/r. Similarly, the renal biomarker urine b2
microglobulin/creatinine ratio declined by 58% in the ABC/
3TC+ATV group (P,0.001) but remained unchanged in the
TDF/FTC+ATV/r group (Figure 3E); the change from baseline
to Week 24 was significantly different (P,0.001) between
treatment groups. Conversely, there were no significant changes
from baseline to Week 24 in any of the biomarkers associated
cardiovascular disease, inflammation or thrombogenesis that were
evaluated (hs-CRP, interleukin-6 and D-dimer) either within or
between treatment groups. (Figure 3F–H).
Discussion
Efficacy and Safety
In this randomized, multicenter study, the percentage of
patients maintaining suppression of HIV-1 RNA below 50
copies/mL at Week 24 was not different between the group
simplifying to ABC/3TC+ATV and the group continuing on
TDF/3TC+ATV/r (87% vs. 87%, respectively, by TLOVR
analysis), and as the two sided 95% CI (27.97% to 8.64%)
stratified by prior ART excluded the predefined non-inferiority
margin of 212%, non-inferiority of the simplification regimen
was established. Confirmed virologic failure .400 copies/mL
occurred in 1% of patients in both groups. The mean increase in
CD4+ cell count from baseline to Week 24 was significantly larger
for ABC/3TC+ATV (+48 cells/mL) than TDF/FTC+ATV/r (+8
cells/mL).
There were few grade 2–4 treatment-related AEs in either
group, but patients treated with TDF/FTC+ATV/r had signifi-
cantly more treatment-emergent or worsening grade 2–4 and
grade 3–4 laboratory abnormalities than patients taking ABC/
3TC+ATV – largely driven by a higher rate of hyperbilirubinemia
in the RTV-containing group. Fasting lipid levels were similar
between treatment groups and varied little between baseline and
Week 24, except for a significant increase in HDL in patients
taking ABC/3TC+ATV.
While induction-maintenance strategies in which RTV is
discontinued once viral suppression has been achieved have been
found to be effective and are now endorsed by DHHS guidelines
[5–14], these studies are different in design from the registrational
studies used to establish the efficacy and tolerability of the fixed
dose combination of ABC/3TC where viremic ART-naı̈ve, HIV-1
infected patients and viremic ART-experienced, HIV-1 infected
patients were evaluated. This study evaluated the ability to
maintain virologic suppression following RTV discontinuation in
an ART-experienced population with HIV-RNA,75 c/mL and
currently receiving RTV-containing therapy. The efficacy and
tolerability of ABC/3TC+ATV demonstrated in this study
complement those of the ARIES trial, which enrolled treatment-
naı̈ve patients to receive 36 weeks of ABC/3TC+ATV/r before
randomizing 419 patients with HIV-1 RNA,50 copies/mL to
maintain or discontinue RTV [13]. Twenty-four weeks after
Figure 2. Median fasting lipid parameters with guideline cutoffs from the National Cholesterol Education Project (NCEP) [17]. *P,
0.001 from baseline to Week 24.
doi:10.1371/journal.pone.0096187.g002
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randomization in that study, viral suppression was maintained in
93% (195/210) of patients taking ABC/3TC+ATV and 89%
(184/209) taking ATC/3TC+ATV/r (by TLOVR). Other data
were reported only after 48 weeks on randomized therapy.
Virologic failure was uncommon (2% overall), but 7 of 8 patients
meeting the criteria for virologic failure were taking ATV/r.
CD4+ cell responses were robust and similar between treatment
groups. Few adverse events were reported after randomization: in
the group discontinuing RTV, the rate of hyperbilirubinemia
decreased from 14% to 4%. Fasting total cholesterol, LDL
cholesterol, and triglycerides increased while patients were taking
ATV/r, and values returned only partway to baseline when RTV
was discontinued. Median HDL cholesterol improved from
38 mg/dl at baseline to 48 mg/dl at Week 84 regardless of
randomized treatment.
Likewise, in the InduMA study, 252 antiretroviral-naı̈ve patients
received 2 NRTIs plus ATV/r for 26 to 30 weeks [8]. Patients
with confirmed HIV-1 RNA,50 copies/mL were randomized to
switch to unboosted ATV (n = 87) or maintain ATV/r (n = 85);
NRTI backbones were not changed (approximately 52% ABC/
3TC and 32% lamivudine/zidovudine). After 48 weeks on
randomized therapy (no data were reported at 24 weeks), there
was no significant difference in the percentage of patients with
HIV-1 RNA,50 copies/mL (78% ATV and 75% ATV/r in an
ITT non-completion = failure analysis). Virologic failure rates
were higher than in our study (13% ATV; 7% ATV/r), but only a
few patients had HIV-1 RNA .400 copies/L (5% ATV; 1%
ATV/r). CD4+ cell counts continued to increase from random-
ization to the end of the 48-week maintenance phase, with no
difference between the ATV (+92 cells/mL) and ATV/r (+100
cells/mL) groups. During the maintenance phase, the prevalence of
hyperbilirubinemia decreased from 32% to 16% in the ATV
group and from 32% to 28% in the ATV/r group. Fasting lipids
favored ATV, with significant improvements in total cholesterol
and triglycerides compared with ATV/r over 48 weeks on
randomized therapy. HDL cholesterol improved in both groups,
and LDL cholesterol levels were stable.
Biomarkers
Bone. We found a significant improvement in markers of
bone turnover following the switch to ABC/3TC+ATV but
observed little change in the group maintaining TDF/FTC+
ATV/r. It has previously been demonstrated that the initiation of
ARV therapy is often associated with decreases in BMD that slow
or stabilize over 24 to 48 weeks of therapy, and that these losses
tend to be larger with TDF-containing regimens compared with
non-TDF-containing regimens [18–21]. Several studies of bone
biomarkers have been performed in treatment-naı̈ve patients
initiating therapy [21–24] but, to our knowledge, only 2 other
randomized trials have included treatment-experienced adults
[25,26]. Results from these two trials were generally consistent
with our findings that bone biomarkers were more favorable in
patients taking ABC/3TC compared with TDF/FTC.
Figure 3. Biomarkers. Geometric means and 95% confidence intervals for bone (bone alkaline phosphatase, parathyroid hormone, C-terminal
telopeptide and osteocalcin), renal (urine b2 microglobulin/creatinine ratio), and inflammatory (high sensitivity C-reactive protein [hs-CRP],
interleukin-6, and d-dimer) biomarkers in patients in both treatment groups with data at baseline and Week 24. Intra-arm P-values were calculated
using a paired t-test on the ratio of the geometric mean concentration at baseline and the geometric mean concentration at Week 24. Inter-arm P-
values were calculated using a two sample t-test on the ratio of the geometric mean change from baseline to Week 24 in the ABC/3TC+ATV vs. TDF/
FTC+ATV/r groups.
doi:10.1371/journal.pone.0096187.g003
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Renal. While the association between TDF and renal
impairment is well studied, (for example, [27–29]) only one other
randomized trial has included urine b2 microglobulin/creatinine
ratio, a validated marker of combined glomerular and tubular
health. ASSERT was open-label study comparing ABC/3TC with
TDF/FTC, both in combination with efavirenz, in treatment-
naı̈ve patients [30]. After 24 weeks on therapy, the b2
microglobulin/creatinine ratio increased by 24% in the TDF/
FTC group and decreased by 28% in the ABC/3TC group. The
difference was statistically significant (P,0.0001) and consistent
with the results observed in our study (albeit in treatment-naive
patients).
Cardiovascular/inflammation. In our study, switching to
ABC/3TC+ATV was not associated with significant changes in
interleukin-6, hs-CRP or d-dimer, markers of inflammation and
coagulation. Other data regarding changes in these markers
following administration of ABC been mixed. Several studies
found no increase in markers of cardiovascular disease with
initiation of ABC compared to other NRTIs, [25,26,29,31–35]
while a metabolic substudy of AIDS Clinical Trials Group
(ACTG) study A5202 reported a significant increase in hs-CRP
at 24 and 96 weeks in treatment naı̈ve patients randomized to
ABC/3TC vs those randomized to TDF/FTC [20]. Interleukin-6
levels declined with both ABC/3TC and TDF/FTC, but the
change was significantly smaller for those receiving ABC/3TC at
week 24 but not week 96. Four other studies have examined
cardiovascular markers in treatment-experienced patients: STEAL
[25], SWAP [26], BICOMBO [32], and SWIFT [36]. As in our
study, none of these trials reported a difference between ABC/
3TC and TDF/FTC in hs-CRP, interleukin-6, or d-dimer over 48
weeks of post-randomization treatment.
There are several limitations of this trial that should be
considered when interpreting these results. The study enrolled
therapy-experienced patients who achieved viral suppression and
had not experienced prior virologic failure leading to selection of
drug resistance mutations; extrapolating these findings to other
patient populations may be inappropriate. Plasma concentrations
of ATV in the absence of RTV boosting are lower, and therefore
this regimen may be more susceptible to patient adherence issues.
Additionally, this simplification treatment strategy is restricted to
certain NRTI backbones such as ABC/3TC that can be used in
combination with unboosted ATV. Lastly, 24 week data are
presented and the efficacy and safety of this simplification strategy
needs to be evaluated over a longer period of time (this study
continues to 48 weeks and follow-up results will be forthcoming).
Conclusion
Over 24 weeks, simplification of TDF/FTC+ATV/r to ABC/
3TC+ATV maintained viral suppression, was well-tolerated, and
led to improvements in CD4+ cell count, bone biomarkers, renal
biomarkers, and HDL cholesterol without causing increases in
other fasting lipid levels or in cardiovascular biomarkers of
inflammation and thrombogenesis. This study continues through
48 weeks to provide longer-term data regarding the efficacy and
safety of this ART simplification strategy.
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